Phase 3Completed
Cardio Protective Effect of SGL2I in Hemodialysis Patients and Its Impact on Patient Quality of Life
Potential Beneficial Cardio Protective Effect of SGL2I in Hemodialysis Patients and Its Impact on Patient Quality of Life
- Sponsor
- Al-Azhar University (Academic or other)
- Enrolment
- 126 enrolled
- Conditions
- Kidney Diseases
- Interventions
- Dapagliflozin (DAPA)
- Ages
- adults, older adults
- Registry
- NCT06759077
From the registry
If this study has a cardio protective effect it will affect the mortality and morbidity of advanced CKD patients and improve their quality of life
Primary outcomes
- Investigate the cardio protective effect of SGL2 inhibitors(DAPAGLIFLOZINE (10 mg/day)) in dialysis patients ,by measuring human N terminal pro brain natriuretic peptide (N -pro BNB) at baseline and after 6months